Abbott Laboratories Surges on Earnings Beat and Guidance Raise

ABT delivered second-quarter 2026 results on July 16 that topped Wall Street estimates, with adjusted EPS of $1.31 against a $1.28 consensus and net sales of $12.59 billion, up roughly 13% on a reported basis. Medical device strength anchored the quarter and drove the upside investors had been waiting for.

Abbott paired the beat with a raised full-year outlook, lifting its 2026 adjusted EPS guidance to $5.45 to $5.60 from a prior $5.38 to $5.58. The guidance raise, rather than the headline beat alone, was the catalyst that reset sentiment on a stock that had lagged for much of the year.

Shares surged about 13% on the session, one of the sharpest single-day moves for ABT in years. With one analyst pointing to a $121 price target, the near-term debate shifts to whether Abbott can sustain the mid-single-digit organic growth that underpinned the quarter, or whether the re-rating already prices in the improved outlook.

Related Stocks

• ABT